April 2024 in “JAMA dermatology” In this randomized clinical trial, oral minoxidil was not superior to topical minoxidil in increasing hair density in men with androgenetic alopecia over 24 weeks, though photographic analysis suggested oral minoxidil may work better on the vertex area of the scalp.
November 2023 in “Journal of Cosmetic Dermatology” This study concluded that while both 5% topical and 1 mg oral minoxidil significantly improved hair diameter in androgenetic alopecia patients, there was no significant difference in overall effectiveness or patient satisfaction between the treatments.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
17 citations
,
November 2021 in “Journal of Cosmetic Dermatology” This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.
9 citations
,
October 2020 in “Journal of The American Academy of Dermatology” This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.
24 citations
,
September 2020 in “Dermatology and therapy” This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.
19 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.
8 citations
,
January 2020 in “Journal of Cutaneous Medicine and Surgery” Oral minoxidil may improve hair loss in men and women, but has some side effects.
24 citations
,
September 2019 in “Journal of The American Academy of Dermatology” This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.
52 citations
,
May 2019 in “Journal of The American Academy of Dermatology” This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.
32 citations
,
January 2019 in “American Journal of Clinical Dermatology” This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.
23 citations
,
October 2018 in “Expert Opinion on Drug Safety” This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.
80 citations
,
December 2017 in “International Journal of Dermatology” This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.
40 citations
,
September 2017 in “F1000Research” In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.
20 citations
,
April 2012 in “Fertility and Sterility” In this laboratory study with rats, treatment with finasteride reduced dihydrotestosterone levels and fertility parameters, with a 30-day recovery period proving insufficient to fully restore sperm function and fertility.
10 citations
,
September 2008 in “Andrologia” In this study, treatment with finasteride altered the expression patterns of antioxidant enzymes in the epididymis of rats, potentially affecting its protective function for spermatozoa.
48 citations
,
February 2006 in “Molecular and Cellular Endocrinology” This study found that dual 5α-reductase inhibitors in rats decreased sperm quality and led to reduced pregnancy success, suggesting potential for use in male contraception.
23 citations
,
July 1996 in “Archives of Dermatological Research” bFGF, VEGF, and minoxidil decrease collagen production in hair cells, possibly affecting hair growth.
35 citations
,
February 1994 in “Fundamental and applied toxicology” High doses of finasteride cause cell growth and tumors in mice.
63 citations
,
September 1987 in “Journal of Biological Chemistry” Minoxidil slows fibroblast growth and collagen production, potentially treating keloids, hypertrophic scars, and connective tissue disorders.
